“…Participants likely overemphasised barriers to PIFU as regular follow‐up users—in practice if PIFU became a standard of care, patients would understand and expect a change in follow up over time from the start of their treatment, and a service using PIFU will have additional capacity due to fewer scheduled appointments. However, PIFU should perhaps be considered as one of a range of follow‐up options, in line with recommendations and patient preference (Gasson et al, 2014 ) for nuanced, flexible follow‐up tailored to individual (Brennan et al, 2019 ; INTEGRATE (UK ENT Trainee Research Network) et al, 2021 ; Wells, Cunningham, et al, 2015 ) and local (Lester & Wight, 2009 ) needs, for example, planned risk‐stratified follow up in a UK HNC clinic (De Felice et al, 2021 ). Cancer stage is also likely to be an important consideration, with PIFU more appropriate for early cancer (Kanatas et al, 2014 ).…”